Animal experiment:

Rats[1]Neuropeptide Y (13-36) dissolved in 30 μL mock cerebrospinal fluid (CSF), or CSF alone, is injected (30/μL/3 min) by means of an automatic micro-injection pump into the lateral ventricle of freely moving, unrestrained male rats. Five doses of Neuropeptide Y (13-36) (25, 75, 750, 1250, 3000 pM) are injected in order to evaluate possible dose-dependent effects and the effects are compared with the CSF group. A threshold dose of Neuropeptide Y (13-36) is also injected together with a dose of Neuropeptide Y (1-36) (75 pM), close to the ED50 value for its overall vasodepressor action in awake rats[1].

Neuropeptide Y (13-36), amide, human is a neuropeptide Y receptor agonist.

Intraventricular injections of the Y2 neuropeptide Y receptor agonist porcine Neuropeptide Y (13-36) (25-3000 pM) produces a dose-dependent increase (up to 14%; ED50=0.3 nM for overall effects and 0.97 nM for the peak effects) in mean arterial blood pressure in the awake, unrestrains male rat without affecting heart rate. Central administration of porcine Neuropeptide Y (13-36) produces marked vasodepressor and bradycardic actions in the anaesthetized α-chloralose and in the awake unrestrained male rat[1].

[1]. Aguirre JA, et al. Centrally injected neuropeptide Y (13-36) produces vasopressor effects and antagonizes the vasodepressor action of neuropeptide Y (1-36) in the awake male rat. Neurosci Lett. 1990 Oct 2;118(1):5-8.